Fujian Sheng Min Dong Li Jie Xun Pharma Co., Ltd. romanized
Check drug filings and source records for this company-name string.
Listed by the company name as recorded in the source, without merging affiliated entities.
Page reference bccfa79fba
These counts cover loaded acceptance records only. First-applicant and co-applicant counts are not added together. CDE data as of 2026/11/13 06:42.
Drug filings
22 acceptance records as first applicant, grouped into 13 source drug names. Source data as of 2026/11/13 06:42.
Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.
富马酸卢帕替芬胶囊 · No verified English name 4 records · Latest accepted 2025/12/16
Supplement · 3New drug · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CXHB2500331 | Supplement | 2025/12/16 | Fujian Sheng Min Dong Li Jie Xun Pharma Co., Ltd. romanized | CDE ↗ |
| CXHB2200037 | Supplement | 2022/03/15 | Fujian Sheng Min Dong Li Jie Xun Pharma Co., Ltd. romanized | CDE ↗ |
| CXHB2200036 | Supplement | 2022/03/15 | Fujian Sheng Min Dong Li Jie Xun Pharma Co., Ltd. romanized | CDE ↗ |
| CXHL2101739 | New drug | 2021/12/15 | Fujian Sheng Min Dong Li Jie Xun Pharma Co., Ltd. romanized | CDE ↗ |
Famotidine,Calcium Carbonate and Magnesium Hydroxide Chewable Tablets 1 records · Latest accepted 2025/04/15
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2550171 | Supplement | 2025/04/15 | Fujian Sheng Min Dong Li Jie Xun Pharma Co., Ltd. romanized | CDE ↗ |
Vortioxetine Hydrobromide Tablets 3 records · Latest accepted 2025/04/10
Supplement · 1Generic · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2500711 | Supplement | 2025/04/10 | Fujian Sheng Min Dong Li Jie Xun Pharma Co., Ltd. romanized | CDE ↗ |
| CYHS2300559 | Generic | 2023/02/18 | Fujian Sheng Min Dong Li Jie Xun Pharma Co., Ltd. romanized | CDE ↗ |
| CYHS2300558 | Generic | 2023/02/18 | Fujian Sheng Min Dong Li Jie Xun Pharma Co., Ltd. romanized | CDE ↗ |
Dihydroxyaluminum Aminoacetate, Heavy Magnesium Carbonate and Aspirin Tablets(Ⅱ) 1 records · Latest accepted 2025/01/24
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2500461 | Generic | 2025/01/24 | Fujian Sheng Min Dong Li Jie Xun Pharma Co., Ltd. romanized | CDE ↗ |
Piracetam Tablets 2 records · Latest accepted 2024/08/17
Supplement · 2
Trazodone Hydrochloride Tablets 2 records · Latest accepted 2024/07/30
Generic · 2
Roxatidine Acetate Hydrochloride For Injection 2 records · Latest accepted 2024/04/30
Supplement · 1Generic · 1
Oseltamivir Phosphate Capsules 1 records · Latest accepted 2024/03/27
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2400923 | Generic | 2024/03/27 | Fujian Sheng Min Dong Li Jie Xun Pharma Co., Ltd. romanized | CDE ↗ |
Oseltamivir Phosphate For Oral Suspension 1 records · Latest accepted 2024/02/01
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2400421 | Generic | 2024/02/01 | Fujian Sheng Min Dong Li Jie Xun Pharma Co., Ltd. romanized | CDE ↗ |
Piracetam Injection 2 records · Latest accepted 2023/07/19
Generic · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2301938 | Generic | 2023/07/19 | Fujian Sheng Min Dong Li Jie Xun Pharma Co., Ltd. romanized; Shandong Luo Xin Pharma Group Co., Ltd. romanized | CDE ↗ |
| CYHS2301937 | Generic | 2023/07/19 | Fujian Sheng Min Dong Li Jie Xun Pharma Co., Ltd. romanized; Shandong Luo Xin Pharma Group Co., Ltd. romanized | CDE ↗ |
Ambroxol Hydrochloride and Clenbuterol Hydrochloride Oral Solution 1 records · Latest accepted 2022/07/29
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2201169 | Generic | 2022/07/29 | Fujian Sheng Min Dong Li Jie Xun Pharma Co., Ltd. romanized; Kui Hua Pharma Group (Ji Zhou) Co., Ltd. romanized | CDE ↗ |
Pantoprazole Sodium For Injection 1 records · Latest accepted 2021/12/08
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2151059 | Supplement | 2021/12/08 | Fujian Sheng Min Dong Li Jie Xun Pharma Co., Ltd. romanized | CDE ↗ |
Omeprazole Sodium for Injection 1 records · Latest accepted 2021/11/15
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2151008 | Supplement | 2021/11/15 | Fujian Sheng Min Dong Li Jie Xun Pharma Co., Ltd. romanized | CDE ↗ |
Changes in the last 90 days
0 events from 2026/08/16 to 2026/11/13. CDE data as of 2026/11/13 06:42; NMPA data as of 2026/11/12 18:32.
This source was last successfully updated at 2026/11/12 18:32; current coverage may be incomplete.
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
- No matching records were found in the currently loaded source data; coverage dates are listed below.
Under review
0 acceptance numbers with this company as first applicant are currently listed as under review by CDE. Source data as of 2026/11/13 06:42.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| No matching records were found in the currently loaded source data; coverage dates are listed below. | |||||
Catalogue holder records
13 loaded active catalogue records whose holder name matches this source company name. Source data as of 2026/11/13 06:39. Manufacturer-only records are excluded.
| Drug | Marketing authorization holder | Manufacturer | Approval number | Approved | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| Dihydroxyaluminum Aminoacetate, Heavy Magnesium Carbonate and Aspirin Tablets(Ⅱ) | Fujian Sheng Min Dong Li Jie Xun Pharma Co., Ltd. romanized | Fujian Sheng Min Dong Li Jie Xun Pharma Co., Ltd. romanized | 国药准字H20265251 | 2026/07/21 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Famotidine,Calcium Carbonate and Magnesium Hydroxide Chewable Tablets | Fujian Sheng Min Dong Li Jie Xun Pharma Co., Ltd. romanized | Fujian Sheng Min Dong Li Jie Xun Pharma Co., Ltd. romanized | 国药准字H20080011 | 2026/05/13 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Trazodone Hydrochloride Tablets | Fujian Sheng Min Dong Li Jie Xun Pharma Co., Ltd. romanized | Fujian Sheng Min Dong Li Jie Xun Pharma Co., Ltd. romanized | 国药准字H20256267 | 2025/12/16 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Trazodone Hydrochloride Tablets | Fujian Sheng Min Dong Li Jie Xun Pharma Co., Ltd. romanized | Fujian Sheng Min Dong Li Jie Xun Pharma Co., Ltd. romanized | 国药准字H20256266 | 2025/12/16 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Oseltamivir Phosphate For Oral Suspension | Fujian Sheng Min Dong Li Jie Xun Pharma Co., Ltd. romanized | Fujian Sheng Min Dong Li Jie Xun Pharma Co., Ltd. romanized | 国药准字H20254807 | 2025/07/08 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Roxatidine Acetate Hydrochloride For Injection | Fujian Sheng Min Dong Li Jie Xun Pharma Co., Ltd. romanized | Fujian Sheng Min Dong Li Jie Xun Pharma Co., Ltd. romanized | 国药准字H20253570 | 2025/03/11 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Oseltamivir Phosphate Capsules | Fujian Sheng Min Dong Li Jie Xun Pharma Co., Ltd. romanized | Fujian Sheng Min Dong Li Jie Xun Pharma Co., Ltd. romanized | 国药准字H20253124 | 2025/01/08 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Piracetam Injection | Fujian Sheng Min Dong Li Jie Xun Pharma Co., Ltd. romanized | Shandong Luo Xin Pharma Group Co., Ltd. romanized | 国药准字H20249776 | 2024/12/25 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Piracetam Injection | Fujian Sheng Min Dong Li Jie Xun Pharma Co., Ltd. romanized | Shandong Luo Xin Pharma Group Co., Ltd. romanized | 国药准字H20249777 | 2024/12/25 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Vortioxetine Hydrobromide Tablets | Fujian Sheng Min Dong Li Jie Xun Pharma Co., Ltd. romanized | Fujian Sheng Min Dong Li Jie Xun Pharma Co., Ltd. romanized | 国药准字H20244342 | 2024/06/28 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Pantoprazole Sodium For Injection | Fujian Sheng Min Dong Li Jie Xun Pharma Co., Ltd. romanized | Fujian Sheng Min Dong Li Jie Xun Pharma Co., Ltd. romanized | 国药准字H20073670 | 2022/11/17 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Omeprazole Sodium for Injection | Fujian Sheng Min Dong Li Jie Xun Pharma Co., Ltd. romanized | Fujian Sheng Min Dong Li Jie Xun Pharma Co., Ltd. romanized | 国药准字H20058490 | 2022/09/09 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Terlipressin for Injection | Fujian Sheng Min Dong Li Jie Xun Pharma Co., Ltd. romanized | Fujian Sheng Min Dong Li Jie Xun Pharma Co., Ltd. romanized | 国药准字H20223270 | 2022/04/29 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.
API registrations
7 loaded active API registrations whose first registered company matches this source company name. Source data as of 2026/11/13 06:41.
| Name | Company / applicant | Registration number | Status | Source update date | View source |
|---|---|---|---|---|---|
| 甲硝唑磷酸二钠 · No verified English name | Fujian Sheng Min Dong Li Jie Xun Pharma Co., Ltd. romanized | Y20190005743 | A | 2025/01/04 | CDE ↗ |
| 棓丙酯 · No verified English name | Fujian Sheng Min Dong Li Jie Xun Pharma Co., Ltd. romanized | Y20190005100 | A | 2025/01/04 | CDE ↗ |
| 葡萄糖酸依诺沙星 · No verified English name | Fujian Sheng Min Dong Li Jie Xun Pharma Co., Ltd. romanized | Y20190005096 | A | 2025/01/04 | CDE ↗ |
| 利福霉素钠 · No verified English name | Fujian Sheng Min Dong Li Jie Xun Pharma Co., Ltd. romanized | Y20190005095 | A | 2025/01/04 | CDE ↗ |
| 卡络磺钠 · No verified English name | Fujian Sheng Min Dong Li Jie Xun Pharma Co., Ltd. romanized | Y20190003878 | A | 2025/01/04 | CDE ↗ |
| 苯巴比妥钠 · No verified English name | Fujian Sheng Min Dong Li Jie Xun Pharma Co., Ltd. romanized | Y20190003870 | A | 2025/01/08 | CDE ↗ |
| 炎琥宁 · No verified English name | Fujian Sheng Min Dong Li Jie Xun Pharma Co., Ltd. romanized | Y20190003868 | A | 2025/01/04 | CDE ↗ |
Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.
Co-applicant records
7 acceptance records name this company after the first applicant. They are listed separately and are not included in first-applicant drug or filing counts. Source data as of 2026/11/13 06:42.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| Emedastine Difumarate Sustained-release Capsules | CYHS2601004 | Generic | 2026/04/30 | Fujian Da Pu Biopharmaceuticals Co., Ltd. romanized; Fujian Sheng Min Dong Li Jie Xun Pharma Co., Ltd. romanized | CDE ↗ |
| 注射用酒石酸吉他霉素 · No verified English name | CYHB2400271 | Supplement | 2024/02/20 | Xizang An Xing Pharmaceuticals Co., Ltd. romanized; Fujian Sheng Min Dong Li Jie Xun Pharma Co., Ltd. romanized | CDE ↗ |
| 注射用利福霉素钠 · No verified English name | CYHB2400176 | Supplement | 2024/01/31 | Xizang An Xing Pharmaceuticals Co., Ltd. romanized; Fujian Sheng Min Dong Li Jie Xun Pharma Co., Ltd. romanized | CDE ↗ |
| 注射用甲磺酸左氧氟沙星 · No verified English name | CYHB2400174 | Supplement | 2024/01/31 | Xizang An Xing Pharmaceuticals Co., Ltd. romanized; Fujian Sheng Min Dong Li Jie Xun Pharma Co., Ltd. romanized | CDE ↗ |
| 注射用甲磺酸左氧氟沙星 · No verified English name | CYHB2400173 | Supplement | 2024/01/31 | Xizang An Xing Pharmaceuticals Co., Ltd. romanized; Fujian Sheng Min Dong Li Jie Xun Pharma Co., Ltd. romanized | CDE ↗ |
| Piracetam Tablets | CYHB2350840 | Supplement | 2023/11/16 | Fujian Sheng Fu Kang Pharma Co., Ltd. romanized; Fujian Sheng Min Dong Li Jie Xun Pharma Co., Ltd. romanized | CDE ↗ |
| Piracetam Tablets | CYHB2350839 | Supplement | 2023/11/16 | Fujian Sheng Fu Kang Pharma Co., Ltd. romanized; Fujian Sheng Min Dong Li Jie Xun Pharma Co., Ltd. romanized | CDE ↗ |
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/13 06:42
- Chemical-drug catalogue
- Last successful update: 2026/11/13 06:39
- Full API register
- Last successful update: 2026/11/13 06:41
- NMPA drug delivery notices
- Last successful update: 2026/11/12 18:32 · Current coverage may be incomplete
First index-page publication dates: 2026-10-29 to 2026-11-13; 2 pages pending. Covers loaded notices only, not a complete historical approval database.
Listed by the company name as recorded in the source, without merging affiliated entities.
This page summarizes loaded records only, without new source queries or collection. Parent companies, subsidiaries, former names and aliases are not merged. Counts from different sources must not be added together. No loaded record does not establish the absence of a filing or registration. Check original records where coverage is incomplete, an update has failed, or a source lies outside the loaded scope.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Drugs with a verified official English name use that name only. Other drug names retain the Chinese source name marked No verified English name; names with a Chinese public page link to that page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized; Chinese company names are not displayed. Marked unverified drug names and original statutory reference numbers may appear in Chinese.
Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.